WO2012165926A3 - 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 - Google Patents

항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 Download PDF

Info

Publication number
WO2012165926A3
WO2012165926A3 PCT/KR2012/004396 KR2012004396W WO2012165926A3 WO 2012165926 A3 WO2012165926 A3 WO 2012165926A3 KR 2012004396 W KR2012004396 W KR 2012004396W WO 2012165926 A3 WO2012165926 A3 WO 2012165926A3
Authority
WO
WIPO (PCT)
Prior art keywords
liver cancer
autoantibody
composition
diagnosing liver
cancer containing
Prior art date
Application number
PCT/KR2012/004396
Other languages
English (en)
French (fr)
Other versions
WO2012165926A2 (ko
Inventor
조은위
허창규
고정헌
우미경
유향숙
황해민
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Priority to CN201280038342.1A priority Critical patent/CN103732627B/zh
Publication of WO2012165926A2 publication Critical patent/WO2012165926A2/ko
Publication of WO2012165926A3 publication Critical patent/WO2012165926A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 ATIC에 특이적으로 결합하는 자가면역항체(autoantibody) 또는 이의 항원결합부위(antigen-binding site, paratope)를 포함하는 단편, 상기 단편의 발현 수준을 측정하는 제제를 포함하는 간암 진단용 조성물, 상기 자가면역항체를 생산하는 하이브리도마 세포주, 상기 조성물을 포함하는 간암 진단용 키트, 상기 조성물을 이용한 간암 진단 방법 및 상기 자가면역항체를 이용한 간암 치료제의 스크리닝 방법에 관한 것이다. 본 발명의 항-ATIC 특이반응 자가면역항체를 간암 진단 마커로 사용하면, 혈액, 혈장, 혈청, 림프액 등과 같은 비침습적 생물학적 시료를 이용하여 약 87%의 민감도와 약 88%의 특이도로 간암의 발병 여부를 진단할 수 있으며, 본 발명에서 동정된 아미노산 서열만을 이용하여 용이하게 간암을 진단할 수 있어 간암 진단용 키트 개발에 효과적이다.
PCT/KR2012/004396 2011-06-02 2012-06-04 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 WO2012165926A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280038342.1A CN103732627B (zh) 2011-06-02 2012-06-04 包含抗-atic自身免疫抗体的肝癌诊断标记物以及包含其抗原的肝癌诊断用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0053509 2011-06-02
KR1020110053509A KR101439856B1 (ko) 2011-06-02 2011-06-02 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물

Publications (2)

Publication Number Publication Date
WO2012165926A2 WO2012165926A2 (ko) 2012-12-06
WO2012165926A3 true WO2012165926A3 (ko) 2013-04-04

Family

ID=47260129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004396 WO2012165926A2 (ko) 2011-06-02 2012-06-04 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물

Country Status (3)

Country Link
KR (1) KR101439856B1 (ko)
CN (1) CN103732627B (ko)
WO (1) WO2012165926A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101750411B1 (ko) 2015-07-10 2017-06-27 한국생명공학연구원 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
CN106432492A (zh) * 2015-08-07 2017-02-22 广州瑞博奥生物技术有限公司 针对肿瘤标志物建立的抗体组合及其elisa方法
CN113820382A (zh) * 2021-09-18 2021-12-21 中国医学科学院医学实验动物研究所 一种新型哺乳动物的异源抗原的筛选方法及其应用
CN114113611B (zh) * 2021-12-13 2023-07-14 郑州大学 一种用于肝癌诊断的生物标志物及检测试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523011A (ja) * 2005-12-01 2009-06-18 メディカル プログノシス インスティテュート 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
WO2009124901A1 (en) * 2008-04-07 2009-10-15 Erasmus University Medical Center Rotterdam Methods and kits for detecting tumor-specific fusion proteins
KR20100112192A (ko) * 2008-02-04 2010-10-18 바이파 사이언스 인코포레이티드 Ｐａｒｐ－매개된 질병을 진단 및 치료하는 방법
KR20110040624A (ko) * 2009-10-12 2011-04-20 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523011A (ja) * 2005-12-01 2009-06-18 メディカル プログノシス インスティテュート 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
KR20100112192A (ko) * 2008-02-04 2010-10-18 바이파 사이언스 인코포레이티드 Ｐａｒｐ－매개된 질병을 진단 및 치료하는 방법
WO2009124901A1 (en) * 2008-04-07 2009-10-15 Erasmus University Medical Center Rotterdam Methods and kits for detecting tumor-specific fusion proteins
KR20110040624A (ko) * 2009-10-12 2011-04-20 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIAN-YING ZHANG ET AL.: "Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors", EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, vol. 10, no. 3, April 2010 (2010-04-01), pages 321 - 328 *
KAREN G. BULOCK ET AL.: "The kinetic mechanism of the human bifunctional enzyme ATIC (5-Amino-4-imidazolecarboxamide ribonucleotide transformylase /inosine 5' -monophosphate cyclohydrolase) - a surprising lack of substrate channeling", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 25, 21 June 2002 (2002-06-21), pages 22168 - 22174 *
RENE STEMPFER ET AL.: "Tumor auto-antibody screening: performance of protein microarrays using SEREX derived antigens", BMC CANCER, vol. 10, 16 November 2010 (2010-11-16), pages 627 *

Also Published As

Publication number Publication date
CN103732627A (zh) 2014-04-16
KR101439856B1 (ko) 2014-09-17
KR20120134547A (ko) 2012-12-12
CN103732627B (zh) 2016-08-17
WO2012165926A2 (ko) 2012-12-06

Similar Documents

Publication Publication Date Title
BR112012008665A2 (pt) tratamento de câncer
JP2015533788A5 (ko)
NZ603492A (en) Humanized anti-factor d antibodies and uses thereof
BR112015014833A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno deste, ácido nucléico isolado, célula hospedeira, método de ensaiar uma amostra de tecido removido de um humano para expressão de pd-l1, estojo, e, composição de anticorpo que compreende uma mistura de moléculas do anticorpo
WO2014036495A4 (en) Diagnostic assays and kits for detection of folate receptor 1
BR112012007365A2 (pt) proteínas de ligação à il-1
JP2017518366A5 (ko)
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
BR112013027867A2 (pt) "método de detectar o nível de um anticorpo anti-ip10 em amostra, anticorpo monoclonal isolado ou porção de ligação de antígeno do mesmo, linhagem de célula de hibridoma e kit"
WO2013068373A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
RU2017139859A (ru) Композиции для обнаружения циркулирующего биомаркера интегрина бета-3 и способы выявления злокачественных новообразований и оценки присутствия или прогрессии опухоли, устойчивости к лекарственным препаратам и опухолевой стволовости
WO2017194499A1 (en) Tissue-specific exosomes as biomarkers
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
WO2012165926A3 (ko) 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
RU2015132142A (ru) Композиции и способы для диагностики и лечения опухоли
MX357292B (es) Método para detectar cáncer.
WO2015138532A2 (en) Methods for the treatment of kidney fibrosis
JP2013543117A5 (ko)
RU2011144835A (ru) Способы и композиции на основе белков для диагностики колоректальной аденокарциномы
AU2016289621A1 (en) Methods and compounds for the alleviation and/or prevention of bone loss
MX2014003065A (es) Anticuerpo monoclonal terapeuticamente activo b7-h6 contra el polipeptido b7-h6.
WO2011046309A3 (en) A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
WO2012112013A3 (en) A marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer
RU2671578C2 (ru) Способ прогнозирования риска возникновения рака или диагностирования рака у женщины

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12793272

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12793272

Country of ref document: EP

Kind code of ref document: A2